{"result": {"id": "cf2efc16-62dd-4e9c-afed-231389477e42", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>BEVACIZUMAB<|>ORGANIZATION<|>A monoclonal antibody drug used in cancer treatment that can cause hypertension\")  \n##\n(\"entity\"<|>SUNITINIB<|>ORGANIZATION<|>An oral anti-angiogenic drug used in cancer therapy associated with blood pressure elevation\")  \n##\n(\"entity\"<|>AMLODIPINE<|>ORGANIZATION<|>A calcium channel blocker used to treat bevacizumab-induced hypertension\")  \n##\n(\"entity\"<|>VASCULAR ENDOTHELIAL GROWTH FACTOR<|>ORGANIZATION<|>A signaling protein targeted by anti-cancer drugs that affects blood pressure regulation\")  \n##\n(\"entity\"<|>CHRONIC OBSTRUCTIVE PULMONARY DISEASE<|>ORGANIZATION<|>A chronic lung disease frequently comorbid with cardiovascular conditions\")  \n##\n(\"entity\"<|>BETA-BLOCKERS<|>ORGANIZATION<|>Cardiovascular medications studied in COPD patients with heightened cardiovascular risk\")  \n##\n(\"entity\"<|>LONG-ACTING MUSCARINIC ANTAGONISTS<|>ORGANIZATION<|>A class of bronchodilators evaluated for cardiovascular safety in COPD\")  \n##\n(\"relationship\"<|>BEVACIZUMAB<|>VASCULAR ENDOTHELIAL GROWTH FACTOR<|>Bevacizumab inhibits VEGF signaling pathway<|>9\")  \n##\n(\"relationship\"<|>SUNITINIB<|>VASCULAR ENDOTHELIAL GROWTH FACTOR<|>Sunitinib targets VEGF receptors<|>9\")  \n##\n(\"relationship\"<|>BEVACIZUMAB<|>AMLODIPINE<|>Amlodipine used to treat bevacizumab-induced hypertension<|>8\")  \n##\n(\"relationship\"<|>CHRONIC OBSTRUCTIVE PULMONARY DISEASE<|>BETA-BLOCKERS<|>Beta-blockers studied in COPD patients with cardiovascular risk<|>7\")  \n##\n(\"relationship\"<|>CHRONIC OBSTRUCTIVE PULMONARY DISEASE<|>LONG-ACTING MUSCARINIC ANTAGONISTS<|>LAMAs evaluated for cardiovascular effects in COPD<|>7\")  \n##\n(\"relationship\"<|>SUMMIT TRIAL<|>CHRONIC OBSTRUCTIVE PULMONARY DISEASE<|>SUMMIT trial studied COPD patients with cardiovascular risk<|>8\")  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559085, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 555, "prompt_tokens": 3891, "total_tokens": 4446, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3840}, "prompt_cache_hit_tokens": 3840, "prompt_cache_miss_tokens": 51}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: :534-543.\n[632]  Ranpura V, PulipatiB, Chu D, et al.  Increased risk of high- grade hypertensionwithbevacizumab incancerpatients: ameta- analysis[J]. Am JHypertens,2010,23(5) :460-468.\n[633]  Maitland ML, BakrisGL, Black HR, etal. Initialassessment,  surveillance, and managementofblood pressure in patients re- ceiving vascularendothelialgrowthfactor signaling pathway in- hibitors[J]. JNatlCancerInst,2010,102(9) :596-604.\n[634]  AziziM, ChedidA, OudardS.  Homeblood-pressuremonitoring inpatientsreceiving sunitinib[J]. N EnglJ Med, 2008, 358(1) :  95-97.\n[635]  LyonAR, López-FernándezT, Couch LS, etal. 2022ESC guide- lineson cardio-oncology developed in collaboration with the Eu- ropean Hematology Association (EHA) , the European Society forTherapeuticRadiology and Oncology (ESTRO) and the In- ternationalCardio-Oncology Society (IC-OS) [J]. Eur Heart J CardiovascImaging,2022,23(10) :e333-e465.\n[636]  EssaH, DobsonR, WrightD, etal.  Hypertensionmanagement in cardio-oncology[J]. J Hum Hypertens, 2020, 34(10) : 673- 681.\n[637]  MirO, CoriatR, RopertS, etal. Treatmentofbevacizumab-in- ducedhypertension by amlodipine[J]. InvestNew Drugs, 2012,  30(2) :702-707.\n[638]  RazviY, Chan S, McFarlaneT, etal. ASCO, NCCN, MASCC/ ESMO: a comparison ofantiemeticguidelinesforthe treatment ofchemotherapy-induced nausea and vomiting in adult patients [J]. SupportCareCancer,2019,27(1) :87-95.\n[639]  NazerB, HumphreysBD, MoslehiJ.  Effectsofnovelangiogen-\n\n\n\n　esisinhibitorsfor the treatmentof cancer on the cardiovascular system: focuson hypertension[J]. Circulation, 2011, 124(15) :  1687-1691.\n[640]  DivoM, CoteC, deTorresJP, etal. Comorbiditiesand risk of mortalityinpatientswith chronicobstructivepulmonarydisease [J]. Am J RespirCritCareMed,2012,186(2) :155-161.\n[641]  Mannino DM, Thorn D, SwensenA, etal. Prevalenceandout- comes of diabetes,  hypertension and cardiovascular disease in COPD[J]. EurRespirJ,2008,32(4) :962-969.\n[642]  中华医学会呼吸病学分会慢性阻塞性肺疾病学组 , 中国医师协 会呼吸医师分会慢性阻塞性肺疾病工作委员会.  慢性阻塞性肺 疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志 ,2021, 44(3) :170-205.\n[643]  DransfieldMT, McAllister DA, Anderson JA, et al. β-Blocker therapy and clinicaloutcomes inpatients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk.  an observationalsubstudyofSUMMIT[J]. Ann Am Tho- racSoc,2018,15(5) :608-614.\n[644]  Yang YL, Xiang ZJ, YangJH, etal.  Association ofβ-blocker usewith survivalandpulmonaryfunctioninpatientswithchron- icobstructivepulmonaryandcardiovasculardisease: asystemat- icreview andmeta-analysis[J]. EurHeartJ,2020,41(46) :4415- 4422.\n[645]  GuleaC, ZakeriR, Alderman V, etal. Beta-blockertherapyin patientswith COPD: a systematic literature review and meta- analysis with multiple treatment comparison[J]. Respir Res,  2021,22(1) :64.\n[646]  ZhangC, ZhangM, WangY, etal. Efficacyand cardiovascular safetyofLAMA inpatientswithCOPD: asystematicreview and meta-analysis[J]. J InvestigMed,2021,69(8) :1391-1398.\n[647]  LiC, ChengW , GuoJ, etal. Relationship ofinhaled long-act- ingbronchodilatorswithcardiovascularoutcomesamongpatients with stableCOPD: a meta-analysis and systematic review of43 randomized trials[J]. IntJ Chron ObstructPulmonDis,2019,4:  799-808.\n[648]  Wu J,  Ye Y, LiC, et al.  Correlation of inhaled long-acting bronchodilatorswith\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>AMERICAN JOURNAL OF HYPERTENSION<|>ORGANIZATION<|>A peer-reviewed medical journal publishing research on hypertension and related conditions\")  \n##\n(\"entity\"<|>JOURNAL OF THE NATIONAL CANCER INSTITUTE<|>ORGANIZATION<|>A leading oncology journal publishing cancer research and clinical guidelines\")  \n##\n(\"entity\"<|>NEW ENGLAND JOURNAL OF MEDICINE<|>ORGANIZATION<|>A prestigious medical journal covering a wide range of clinical and research topics\")  \n##\n(\"entity\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>ORGANIZATION<|>A professional organization that develops cardiovascular guidelines, including cardio-oncology\")  \n##\n(\"entity\"<|>EUROPEAN HEMATOLOGY ASSOCIATION<|>ORGANIZATION<|>A medical society focused on hematology research and practice\")  \n##\n(\"entity\"<|>EUROPEAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY<|>ORGANIZATION<|>A professional group specializing in radiation oncology\")  \n##\n(\"entity\"<|>INTERNATIONAL CARDIO-ONCOLOGY SOCIETY<|>ORGANIZATION<|>An organization dedicated to the intersection of cardiovascular disease and cancer\")  \n##\n(\"entity\"<|>AMERICAN SOCIETY OF CLINICAL ONCOLOGY<|>ORGANIZATION<|>A leading oncology professional organization that publishes treatment guidelines\")  \n##\n(\"entity\"<|>NATIONAL COMPREHENSIVE CANCER NETWORK<|>ORGANIZATION<|>An alliance of cancer centers that develops clinical practice guidelines\")  \n##\n(\"entity\"<|>CHINESE MEDICAL ASSOCIATION<|>ORGANIZATION<|>A professional medical organization in China that publishes clinical guidelines\")  \n##\n(\"entity\"<|>V. RANPURA<|>PERSON<|>Researcher who co-authored a meta-analysis on hypertension risk with bevacizumab\")  \n##\n(\"entity\"<|>M.L. MAITLAND<|>PERSON<|>Researcher who co-authored guidelines on blood pressure management in patients receiving VEGF inhibitors\")  \n##\n(\"entity\"<|>M. AZIZI<|>PERSON<|>Researcher who studied home blood-pressure monitoring in patients receiving sunitinib\")  \n##\n(\"entity\"<|>A.R. LYON<|>PERSON<|>Researcher involved in developing ESC cardio-oncology guidelines\")  \n##\n(\"entity\"<|>H. ESSA<|>PERSON<|>Researcher who studied hypertension management in cardio-oncology\")  \n##\n(\"entity\"<|>B. NAZER<|>PERSON<|>Researcher who studied cardiovascular effects of angiogenesis inhibitors\")  \n##\n(\"entity\"<|>SUMMIT TRIAL<|>EVENT<|>A clinical trial studying outcomes in COPD patients with cardiovascular risk\")  \n##\n(\"relationship\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>EUROPEAN HEMATOLOGY ASSOCIATION<|>Collaborated on developing cardio-oncology guidelines<|>7\")  \n##\n(\"relationship\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>INTERNATIONAL CARDIO-ONCOLOGY SOCIETY<|>Collaborated on developing cardio-oncology guidelines<|>7\")  \n##\n(\"relationship\"<|>AMERICAN SOCIETY OF CLINICAL ONCOLOGY<|>NATIONAL COMPREHENSIVE CANCER NETWORK<|>Both organizations develop antiemetic guidelines for chemotherapy-induced nausea<|>6\")  \n##\n(\"relationship\"<|>V. RANPURA<|>AMERICAN JOURNAL OF HYPERTENSION<|>Published research on bevacizumab-induced hypertension<|>8\")  \n##\n(\"relationship\"<|>M.L. MAITLAND<|>JOURNAL OF THE NATIONAL CANCER INSTITUTE<|>Published guidelines on blood pressure management in cancer patients<|>8\")  \n##\n(\"relationship\"<|>M. AZIZI<|>NEW ENGLAND JOURNAL OF MEDICINE<|>Published research on home blood-pressure monitoring in sunitinib patients<|>8\")  \n##\n(\"relationship\"<|>A.R. LYON<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>Contributed to ESC cardio-oncology guidelines<|>9\")  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_30d8674d04dc408cae02804193b95c656536e049dff5eff44cdbff33841b8ac9_v2"}